Timing of Glycoprotein IIb/IIIa Inhibitor Use and Outcomes Among Patients With Non–ST-Segment Elevation Myocardial Infarction Undergoing Percutaneous Coronary Intervention (Results from CRUSADE)
Pierluigi Tricoci(CSL (United States)), Matthew T. Roe(Clinical Research Institute), E. Magnus Ohman(Tarzana Treatment Centers), Charles V. Pollack, Robert A. Harrington(Clinical Research Institute), Anita Y. Chen(University of Rochester Medicine), James W. Hoekstra(Wake Forest University), Eric D. Peterson, W. Brian Gibler(University of Cincinnati), Adam B. Greenbaum(Brigham and Women's Hospital), C. Michael Gibson(Baim Institute for Clinical Research), L. Kristin Newby(Duke University)
Cited by 22
Related Papers
Ticagrelor versus Clopidogrel in Patients with Acute Coronary Syndromes
|New England Journal of Medicine|2009|7.1k
2014 AHA/ACC Guideline for the Management of Patients With Non–ST-Elevation Acute Coronary Syndromes
|Journal of the American College of Cardiology|2014|3.6k
Alirocumab and Cardiovascular Outcomes after Acute Coronary Syndrome
|New England Journal of Medicine|2018|3.5k
Albiglutide and cardiovascular outcomes in patients with type 2 diabetes and cardiovascular disease (Harmony Outcomes): a double-blind, randomised placebo-controlled trial
|The Lancet|2018|1.8k
2016 ACC/AHA Guideline Focused Update on Duration of Dual Antiplatelet Therapy in Patients With Coronary Artery Disease
|Journal of the American College of Cardiology|2016|1.6k